In Vitro and In Vivo Antifungal Activity of Buparvaquone against Sporothrix brasiliensis

Sporotrichosis has become an important zoonosis in Brazil, and is the primary species transmitted by cats. Improvement of animal treatment will help control and limit the spread and geographic expansion of sporotrichosis. Accordingly, buparvaquone, an antiprotozoal hydroxynaphthoquinone agent market...

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial agents and chemotherapy Vol. 65; no. 9; p. e0069921
Main Authors Borba-Santos, Luana Pereira, Barreto, Thayná Lopes, Vila, Taissa, Chi, Kung Darh, Dos Santos Monti, Fabiana, de Farias, Marconi Rodrigues, Alviano, Daniela S, Alviano, Celuta S, Futuro, Débora O, Ferreira, Vitor, de Souza, Wanderley, Ishida, Kelly, Rozental, Sonia
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 17.08.2021
Subjects
Animals
Antifungal Agents - pharmacology
Antifungal Agents - therapeutic use
Cats
Experimental Therapeutics
Microbial Sensitivity Tests
Naphthoquinones
Sporothrix
Sporotrichosis - drug therapy
antifungal
naphthoquinone
sporotrichosis
antifungal agents
cat
Sporothrix spp
zoonosis
Online AccessGet full text

Cover

More Information
Summary:Sporotrichosis has become an important zoonosis in Brazil, and is the primary species transmitted by cats. Improvement of animal treatment will help control and limit the spread and geographic expansion of sporotrichosis. Accordingly, buparvaquone, an antiprotozoal hydroxynaphthoquinone agent marketed as Butalex, was evaluated and against feline-borne isolates of . Buparvaquone inhibited fungal growth at concentrations 4-fold lower than itraconazole (the first-choice antifungal used for sporotrichosis) and was 408 times more selective for than mammalian cells. Yeasts treated with a subinhibitory concentration of buparvaquone exhibited mitochondrial dysfunction, reactive oxygen species and neutral lipid accumulation, and impaired plasma membranes. Scanning electron microscopy images also revealed buparvaquone altered cell wall integrity and induced cell disruption. experiments in a Galleria mellonella model revealed that buparvaquone (single dose of 5 mg/kg of body weight) is more effective than itraconazole against infections with yeasts. Combined, our results indicate that buparvaquone has a great and antifungal activity against , revealing the potential application of this drug as an alternative treatment for feline sporotrichosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Citation Borba-Santos LP, Barreto TL, Vila T, Chi KD, dos Santos Monti F, de Farias MR, Alviano DS, Alviano CS, Futuro DO, Ferreira V, de Souza W, Ishida K, Rozental S. 2021. In vitro and in vivo antifungal activity of buparvaquone against Sporothrix brasiliensis. Antimicrob Agents Chemother 65:e00699-21. https://doi.org/10.1128/AAC.00699-21.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.00699-21